The stock of Insys Therapeutics Inc (NASDAQ:INSY) hit a new 52-week low and has $9.78 target or 8.00% below today’s $10.63 share price. The 9 months bearish chart indicates high risk for the $703.72 million company. The 1-year low was reported on Nov, 3 by Barchart.com. If the $9.78 price target is reached, the company will be worth $56.30M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 455,109 shares traded hands. Insys Therapeutics Inc (NASDAQ:INSY) has declined 38.99% since April 1, 2016 and is downtrending. It has underperformed by 40.21% the S&P500.
Insys Therapeutics Inc (NASDAQ:INSY) Ratings Coverage
Out of 4 analysts covering Insys Therapeutics (NASDAQ:INSY), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Insys Therapeutics has been the topic of 9 analyst reports since August 4, 2015 according to StockzIntelligence Inc. The company was maintained on Thursday, September 22 by RBC Capital Markets. The rating was maintained by JMP Securities with “Market Outperform” on Wednesday, March 9. Oppenheimer maintained the stock with “Hold” rating in Tuesday, August 4 report. The rating was downgraded by Zacks to “Buy” on Friday, August 14. As per Monday, October 10, the company rating was maintained by Jefferies. As per Thursday, August 4, the company rating was maintained by Jefferies. The stock of Insys Therapeutics Inc (NASDAQ:INSY) has “Buy” rating given on Thursday, April 14 by Janney Capital. Jefferies maintained it with “Buy” rating and $23 target price in Wednesday, February 24 report. The company was maintained on Tuesday, April 12 by Jefferies.
According to Zacks Investment Research, “Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. It is engaged in the development and commercialization of pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company’s cancer-supportive care and cancer therapy product candidates include Fentanyl sublingual spray and Dronabinol SG capsule. Insys Therapeutics, Inc. is based in Phoenix, Arizona.”
Insitutional Activity: The institutional sentiment decreased to 0.7 in 2016 Q2. Its down 0.36, from 1.06 in 2016Q1. The ratio worsened, as 22 funds sold all Insys Therapeutics Inc shares owned while 42 reduced positions. 13 funds bought stakes while 32 increased positions. They now own 31.30 million shares or 9.76% less from 34.69 million shares in 2016Q1.
Moreover, Pnc Finance Serv Gru has 0% invested in Insys Therapeutics Inc (NASDAQ:INSY) for 968 shares. Moreover, Blackrock has 0% invested in Insys Therapeutics Inc (NASDAQ:INSY) for 45,105 shares. Nationwide Fund Advsr holds 15,183 shares or 0% of its portfolio. Credit Suisse Ag has invested 0% of its portfolio in Insys Therapeutics Inc (NASDAQ:INSY). Adage Capital Partners Group Inc Ltd Liability Company owns 275,000 shares or 0.01% of their US portfolio. California Pub Employees Retirement, a California-based fund reported 88,600 shares. Parametric Assocs Limited Company holds 0% of its portfolio in Insys Therapeutics Inc (NASDAQ:INSY) for 15,197 shares. American International Inc reported 13,525 shares or 0% of all its holdings. Blackrock accumulated 0% or 93,015 shares. Proshare Advisors Limited Liability Corporation holds 0.01% of its portfolio in Insys Therapeutics Inc (NASDAQ:INSY) for 56,136 shares. Dimensional Fund Advsr Lp holds 0% of its portfolio in Insys Therapeutics Inc (NASDAQ:INSY) for 581,756 shares. Sphera Funds Management holds 0.06% or 16,407 shares in its portfolio. Blackrock Japan Limited has invested 0% of its portfolio in Insys Therapeutics Inc (NASDAQ:INSY). Citigroup owns 18,511 shares or 0% of their US portfolio. Next Financial Gp reported 180 shares or 0% of all its holdings.
Insider Transactions: Since May 11, 2016, the stock had 2 buys, and 4 insider sales for $170,592 net activity. JOHN N KAPOOR TRUST DATED SEPTEMBER 20 1989 had bought 50,000 shares worth $641,827 on Wednesday, May 11. STANLEY THEODORE H had sold 16,000 shares worth $260,320. FOURTEAU PATRICK also sold $276,900 worth of Insys Therapeutics Inc (NASDAQ:INSY) on Thursday, August 11. Shares for $110,752 were sold by BRENNAN DANIEL.
Another recent and important Insys Therapeutics Inc (NASDAQ:INSY) news was published by Forbes.com which published an article titled: “Insys Therapeutics Pops On Earnings Beat, But Revenues Plunge” on November 03, 2016.
INSY Company Profile
Insys Therapeutics, Inc., incorporated on June 15, 1990, is a commercial-stage specialty pharmaceutical company. The Firm develops and commercializes supportive care products. Subsys is the Company’s marketed product. Subsys is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and is a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue. The Firm markets Subsys through its field sales force focused on supportive care physicians in the United States.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.